Hypertension Drugs Market Size To Gain USD 34,072 Million Revenue By 2030 At 3.4% CAGR During 2022 to 2030

Global hypertension drugs market size is estimated to be reach at USD 34,072 million by 2030, with a CAGR of 3.4% over the forecasting years of 2022-2030, as per the Acumen Research and Consulting.

Hypertension Drugs Market Report Statistics

• Global hypertension drugs market value was worth USD 25,394 Million in 2021, with a 3.4% CAGR from 2022 to 2030
• North America hypertension drugs market is expected to lead with more than 35% market share
• By product type, beta blockers segment attained more than 30% of total market share
• According to the CDC, hypertension contributed to more than 670,000 deaths in the US in 2020
• Various government programs and large investments in R&D, propelling the hypertension drugs market revenue

Request For Free Sample Report @

https://www.acumenresearchandconsulting.com/request-sample/2865

Hypertension Drugs Market Report Coverage:

The expansion of the hypertension drugs market size has been driven by primary factors such as an increase in sudden cases of hypertensive disorders worldwide. Diabetes patients, technological advancements, and an elderly workforce are the primary factors driving the hypertension drugs market growth. Furthermore, increased healthcare expenses, a rise in cardiovascular events, and an increase in tobacco users are driving the market growth.

High blood pressure, often known as hypertension, increases the risk of coronary illness and stroke. Obesity, heavy alcohol intake, smoking, as well as a hypertension family history are all major risk factors for hypertension. Beta-blockers are routinely used to treat high blood pressure. High blood pressure (hypertension) is a frequent condition in which the long-term stress of the blood against the artery walls is sufficient to lead to health complications, including coronary heart disease. Hypertension drugs are prescribed to treat individuals who have high blood pressure.

Hypertension Drugs Market Dynamics

According to the World Health Organization (WHO), approximately 1.13 billion people worldwide suffer from hypertension, with only one in every five being treated or under control. A poor diet, frequent alcohol intake, a lack of physical activity, and tobacco use are the main drivers of the development of the hypertension drugs market trend. Hypertension can be the major cause of hemorrhagic, ischemic, as well as coronary heart disease. According to the WHO, high blood pressure is one of the leading causes of mortality and among the most serious public health challenges in the twenty-first century. Hypertension accounts for 12.8% of all global fatal accidents, implying that 7.5 billion deaths are caused by hypertension or high blood pressure. In 2008, the worldwide incidence of hypertension in individuals over the age of 25 was approximately 40%. Furthermore, due to rapid population expansion, namely the aging population, uncontrolled hypertension surpassed 1 billion from 600 million instances in 2008. In Africa, the incidence of hypertension was much more than 40%, and lower in North America is 35%.

Besides this, one of the major limitations in the market is a lack of public awareness about the usage of antihypertensive drugs. Second, individuals suffering from high blood pressure do not stick to their medication schedule and quit taking it after 1-2 weeks until their symptoms return, creating a significant threat to the hypertension drugs market. The market for antihypertensive medications may be hampered by a lack of awareness and adherence to the drugs.

Check the detailed table of contents of the report @

https://www.acumenresearchandconsulting.com/table-of-content/hypertension-drugs-market

Hypertension Drugs Market Segmentation

The global hypertension drugs market has been segmented by Acumen Research and Consulting based on product type, condition, distribution channel, and medication type. Based on type, the industry can be divided into Alpha-Blockers, Diuretics, Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE), Beta-blockers, Vasodilators, Inhibitors, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), and others. The condition category is even further classified into primary hypertension and secondary hypertension. The medication types are listed as monotherapy, combination therapy, and fixed-dose combinations. The distribution channel is further segmented into online pharmacies, retail pharmacies, and hospital pharmacies.

Hypertension Drugs Market Regional Outlook

The global Hypertension Drugs market is divided into five geographic regions: Asia-Pacific, Europe, North America, Latin America, and the Middle East and Africa. According to the hypertension drugs industry analysis, the North American region has the largest market share in terms of revenue in the global market and is expected to continue in the near future. The simple availability of hypertension medicines in the United States and Canada is also driving regional expansion. The rise in the elderly population in this region, which has resulted in an increase in hypertension occurrences, is contributing to the expansion of the regional market.

In terms of annual growth, the Asia-Pacific region is predicted to develop at the quickest rate over the projection period. This is related to increased awareness of hypertension-treatment medicines. The life science business is continually growing in Asia-Pacific emerging countries such as India, Japan, China, and others, resulting in the increased need for hypertension medications in the coming few years.

Buy this premium research report –

https://www.acumenresearchandconsulting.com/buy-now/0/2865

Hypertension Drugs Market Players

Some of the prominent hypertension drugs market companies are Takeda Pharmaceutical Co., Abbott, Sanofi, Johnson and Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., F. Hoffmann La-Roche Ltd., Astrazeneca, Novartis, Gilead, Bayer AG, GlaxoSmithKline Plc., and others.

• On December 2018, Bayer AG announced that the company had received a product designation from the FDA (Food and Drug Administration) for artificial intelligence technology for Chronic Thromboembolic Pulmonary Hypertension (CTPH) Pattern Recognition.

Browse More Research Topic on Healthcare Related:

The global veterinary dermatology drugs market accounted USD 7.8 Billion in 2020 with a significant CAGR of 9.6% during the forecast period of 2021 to 2028.

The global diabetes associated ophthalmic treatment market accounted for USD 26.14 Billion in 2020 with a considerable CAGR of 6.9% during the forecast period of 2021 to 2028.

The global anti-allergic drugs market is expected to grow at a CAGR of around 6.8% from 2020 to 2027 and expected to reach the market value of around USD 39.5 Billion by 2027.

About Acumen Research and Consulting:

Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

For Latest Update Follow Us on Twitter and, LinkedIn

Contact Us:

Mr. Richard Johnson

Acumen Research and Consulting

USA: +1 347 474 3864

India: +91 8983225533

E-mail: sales@acumenresearchandconsulting.com